Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

irinotecan liposome HR070803

A liposomal formulation of the semisynthetic camptothecin analogue irinotecan, with potential antineoplastic activity. Upon administration of irinotecan liposome HR070803, irinotecan selectively stabilizes topoisomerase I-DNA covalent complexes during the S phase of the cell cycle, inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing lethal double-strand DNA breaks when complexes are encountered by the DNA replication machinery. Liposome encapsulation of this agent promotes efficient drug delivery into the cytosol from the endosome compartment of the cell.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	liposomal irinotecan HR070803
Code name:	HR 070803 HR-070803 HR070803

irinotecan liposome HR070803

Search NCI's Drug Dictionary